Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

New semi-automatic cell–adhesion assay platform mimics a human capillary

Cellix : 29 January, 2008  (New Product)
Cellix has launched the VenaFlux Platform, the first semi-automated, high throughput microfluidic cell-based assay system that measures cell adhesion to antibody-coated or endothelial-cell cultured microchannels and produces IC50 curves under shear stress conditions mimicking physiological flow.
The system offers scientists a tool for drug discovery. The VenaFlux is simple to use, reduces costly layers of animal model studies, and delivers specific, accurate, and reproducible results.

Using the VenaFlux, scientists can rapidly obtain quantitative analyses and results for potential drug candidates in therapeutic areas including cardiovascular, respiratory, immunologic, autoimmune and oncologic disease states. Relatively rapid analyses reduce drug development costs by accelerating false lead elimination and increasing productivity in pharmaceutical and biotechnology research and development laboratories.

'Understanding how cells behave in human capillaries is an expanding area in global research and development for discovering new patient therapies,' said Vivienne Williams, CEO of Cellix. 'Our VenaFlux accurately replicates cell behaviour in human capillaries, an in vitro modelling system that has previously been difficult to achieve.


Cellix's technology provides researchers with a single platform for executing dynamic studies to analyse the effects of drugs on cell adhesion, proliferation and transmigration under well-defined shear stress protocols that replicate physiological conditions. 'To date, pharmaceutical companies including AstraZeneca and Amgen, as well as research institutions such as the US National Institutes of Health have adopted Cellix's technology to characterise drug effects,' commented Williams.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo